BOLD - Audentes Therapeutics, Inc.
| Previous Close | 39.94 |
| Open | 39.66 |
| Bid | 38.17 x 800 |
| Ask | 38.24 x 900 |
| Day's Range | 38.07 - 39.93 |
| 52 Week Range | 17.95 - 46.18 |
| Volume | 142,009 |
| Avg. Volume | 585,870 |
| Market Cap | 1.699B |
| Beta (3Y Monthly) | 1.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.81 |
| Earnings Date | Aug 8, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.91 |
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of BOLD earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Audentes Therapeutics Inc Earnings Call
Motley Fool•14 days agoAudentes Therapeutics, Inc. (BOLD) Q1 2019 Earnings Call Transcript
BOLD earnings call for the period ending March 31, 2019.
- PR Newswire•14 days ago
Audentes Therapeutics to Participate in the Bank of America Merrill Lynch 2019 Health Care Conference
SAN FRANCISCO , May 8, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious ...
- Associated Press•15 days ago
Audentes Therapeutics: 1Q Earnings Snapshot
On a per-share basis, the San Francisco-based company said it had a loss of $1.13. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
- PR Newswire•15 days ago
Audentes Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Recently presented positive new data from ASPIRO, the Phase 1/2 study of AT132 for treatment of XLMTM - On track to submit updated ASPIRO data package with optimal dose selection to FDA in the second ...
- Insider Monkey•20 days ago
Hedge Funds Have Never Been This Bullish On Audentes Therapeutics, Inc. (BOLD)
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
- PR Newswire•21 days ago
Audentes Therapeutics Presents New Positive Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 for X-linked Myotubular Myopathy, at 22nd Annual Meeting of the American Society of Gene and Cell Therapy
- New data include 48 weeks of follow-up for six treated patients in dose Cohort 1 and 24 weeks for three treated patients in dose Cohort 2 - Significant and sustained improvements in neuromuscular function ...
- PR Newswire•22 days ago
Audentes Therapeutics to Release First Quarter 2019 Financial Results and Provide Corporate Update on Tuesday, May 7, 2019
SAN FRANCISCO , April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for ...
- PR Newswire•26 days ago
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 26, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, announced it has granted equity awards on April 24, 2019, that were previously approved by the Compensation Committee of its Board of Directors under the Audentes Therapeutics, Inc. 2018 Equity Inducement Plan, as a material inducement to employment to nine individuals hired by Audentes from April 2 through April 24, 2019. The options have an exercise price of $40.56 per share, which is equal to the closing price of Audentes common stock on April 24, 2019. One-fourth of the shares underlying each employee's option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee's option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee's continued employment with Audentes on such vesting dates.
- PR Newswire•29 days ago
Audentes Therapeutics Announces Launch of New State-of-the-Art Internal cGMP Plasmid Manufacturing Facility
SAN FRANCISCO, April 23, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, today announced the launch of a new state-of-the-art, internal cGMP plasmid manufacturing facility in South San Francisco. Ensuring access to a reliable supply of high-quality plasmids is a critical aspect of gene therapy development.
- Simply Wall St.•last month
Estimating The Fair Value Of Audentes Therapeutics, Inc. (NASDAQ:BOLD)
Does the April share price for Audentes Therapeutics, Inc. (NASDAQ:BOLD) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's v...
- PR Newswire•last month
Audentes Therapeutics Announces Upcoming Presentations at 22nd Annual Meeting of the American Society of Gene and Cell Therapy Including New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
- Oral presentation of ASPIRO results to include new data, with up to 48-weeks of follow-up for all patients in dose Cohort 1 and up to 24-weeks in the earliest patients in dose Cohort 2 - Presentation ...
- Zacks•last month
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- PR Newswire•last month
Audentes Therapeutics Announces Expansion of AAV Technology Platform and Pipeline with New Development Programs for Duchenne Muscular Dystrophy and Myotonic Dystrophy
- Platform expansion combines the delivery power of AAV with the precision tools of antisense oligonucleotides to develop best-in-class treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy ...
- PR Newswire•2 months ago
Audentes Therapeutics Appoints Legal and Corporate Communications Executives; Promotes Thomas P. Soloway to Executive Vice President and Chief Financial Officer
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Mark A. Meltz, J.D. has joined the company as Senior Vice President, General Counsel and Sarah J. Spencer has joined the company as Vice President, Corporate Communications. In addition, Thomas P. Soloway, currently Senior Vice President, Chief Financial Officer, has been promoted to the newly created position of Executive Vice President, Chief Financial Officer. Tom will continue to lead the finance, accounting, and investor relations functions. Mark will lead the legal, compliance, and corporate governance functions. Sarah will be responsible for internal and external communications to build global awareness of the company, its mission, culture, and innovative product portfolio.
- GlobeNewswire•2 months ago
Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex — New Research Emphasizes Economic Growth
NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Investor's Business Daily•2 months ago
Spark Unlikely To Get A Better Bid — But These Stocks Could Be In Play
Spark Therapeutics is unlikely to get a better offer than Roche's $4.8 billion bid, an analyst says, suggesting instead a pair of other gene therapy names could garner buyout interest.
- Investopedia•2 months ago
10 Stocks For The Gene Therapy Revolution
Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.
- Simply Wall St.•2 months ago
Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year
It is doubtless a positive to see that the Audentes Therapeutics, Inc. (NASDAQ:BOLD) share price has gained some 39% in the last three months. But in truth the last yearRead More...
- Zacks•2 months ago
Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know
Audentes Therapeutics (BOLD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Audentes Therapeutics Inc Earnings Call
- GuruFocus.com•3 months ago
Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018
Audentes Therapeutics Inc (NASDAQ:BOLD) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
